{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T17:42:06.865274+00:00","company":{"ticker":"XLO","cik":1840233,"company_name":"Xilio Therapeutics, Inc."},"pagination":{"limit":100,"returned":36,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Gilead Sciences, Inc.","detail":"equity_purchase","count":3,"first_seen":"2024-03-28T23:59:59+00:00","last_seen":"2024-03-28T23:59:59+00:00","evidence_fact_ids":[64558,64559,64560]},{"display_name":"Leerink Partners LLC","detail":"underwriting","count":1,"first_seen":"2026-02-12T23:59:59+00:00","last_seen":"2026-02-12T23:59:59+00:00","evidence_fact_ids":[32569]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"1b665519cbb6b48c2288b2f70e39b97846a38bcd","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-06-12T20:05:16+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-10","outcome":"passed","proposal_text":"Election of Class II directors","proposal_type":"director_election","results":[{"broker_non_votes":"1,279,671","subject":"Akintunde Bello, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"3,652,015","votes_withheld":"130,437"},{"broker_non_votes":"1,279,671","subject":"Daniel Curran, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"3,709,598","votes_withheld":"72,854"},{"broker_non_votes":"1,279,671","subject":"Robert Ross, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"3,719,795","votes_withheld":"62,657"},{"broker_non_votes":"1,279,671","subject":"Yuan Xu, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"3,716,549","votes_withheld":"65,903"}]},"claim":"Xilio Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-10 meeting.","evidence_excerpt":"On June 10, 2026, the Company held the 2026 Annual Meeting. The following is a summary of the matters voted on at that meeting and the results of the votes on such matters. 1. The Company’s stockholders elected Akintunde Bello, Ph.D., Daniel Curran, M.D., Robert Ross, M.D. and Yuan Xu, Ph.D., as Class II directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: Votes For Votes Withheld Broker Non-Votes Akintunde Bello, Ph.D. 3,652,015 130,437 1,279,671 Daniel Curran, M.D. 3,709,598 72,854 1,279,671 Robert Ross, M.D. 3,719,795 62,657 1,279,671 Yuan Xu, Ph.D. 3,716,549 65,903 1,279,671","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-269358","anchor_url":"https://secwatch.observer/filing/0001193125-26-269358#claim-1b665519cbb6b48c2288b2f70e39b97846a38bcd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526269358/0001193125-26-269358-index.htm"},{"fact_type":"earnings_release","fact_key":"cb03b6665bc48d453a84846eebe4bfe71a64fa94","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-05-12T11:35:15+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-12","result_type":"reported_results","revenue_text":"$12.6 million"},"claim":"Xilio Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: revenue $12.6 million.","evidence_excerpt":"Collaboration and license revenue was $12.6 million for the quarter ended March 31, 2026, compared to $2.9 million for the quarter ended March 31, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-218194","anchor_url":"https://secwatch.observer/filing/0001193125-26-218194#claim-cb03b6665bc48d453a84846eebe4bfe71a64fa94","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526218194/0001193125-26-218194-index.htm"},{"fact_type":"equity_issuance","fact_key":"ea29a476ae063dd73cb6a9496196be62098434c1","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-03-12T23:59:59+00:00","payload":{"action":"rights_modification","consideration_text":null,"effective_date":"2026-03-13","item_codes_triggered":["3.03"],"purchaser":null,"security_type":"common_stock","shares_text":null},"claim":"Xilio Therapeutics, Inc. issued common stock.","evidence_excerpt":"will implement a 1-for-14 reverse stock split of the issued shares of the company’s common stock, effective at 5:00 p.m. Eastern Time on March 13, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-103150","anchor_url":"https://secwatch.observer/filing/0001193125-26-103150#claim-ea29a476ae063dd73cb6a9496196be62098434c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm"},{"fact_type":"governance_change","fact_key":"e52caf3232930681e0ad73536264cbfa6f1dd56f","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-03-12T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-03-13","item_codes_triggered":["5.03"],"summary_text":"Filed a Certificate of Amendment to effect a 1-for-14 reverse stock split of common stock."},"claim":"Xilio Therapeutics, Inc.: Filed a Certificate of Amendment to effect a 1-for-14 reverse stock split of common stock (effective 2026-03-13).","evidence_excerpt":"On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-103150","anchor_url":"https://secwatch.observer/filing/0001193125-26-103150#claim-e52caf3232930681e0ad73536264cbfa6f1dd56f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm"},{"fact_type":"material_agreement","fact_key":"302dd3b1599a5dc0a63fc8ed3632f44471eab53f","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2026-02-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Leerink Partners LLC","effective_date":"2026-02-11","item_codes_triggered":["1.01"],"value_text":"approximately $37.1 million"},"claim":"Xilio Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC valued at approximately $37.1 million (effective 2026-02-11).","evidence_excerpt":"On February 11, 2026, Xilio Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative of the underwriter named therein (the “Underwriter”), relating to an underwritten offering (the “Offering”) of pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 74,780,300 shares of common stock (the “Warrant Shares”) at a price to investors of $0.5349 per Pre-Funded Warrant.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-048942","anchor_url":"https://secwatch.observer/filing/0001193125-26-048942#claim-302dd3b1599a5dc0a63fc8ed3632f44471eab53f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312526048942/0001193125-26-048942-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"a5d02972f4cf54cb438c12d1056de412443bddff","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-10-03T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-03-30","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$1.00 minimum bid price","notice_date":"2025-04-08","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(a)(1)","5810(c)(3)(H)"],"rules_cited_in_text":true},"claim":"Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(H)).","evidence_excerpt":"April 8, 2025 , the Company received a letter from the Staff of Nasdaq notifying the Company of its failure to maintain the $1.00 minimum bid price required for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). In connection with the transfer to The Nasdaq Capital Market, Nasdaq granted the Company an additional 180 calendar day period, or until March 30, 2026, to regain compliance with the Minimum Bid Price Requirement. During the additional 180 calendar day grace period, the Company’s common stock must close at $1","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-229231","anchor_url":"https://secwatch.observer/filing/0001193125-25-229231#claim-a5d02972f4cf54cb438c12d1056de412443bddff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000119312525229231/0001193125-25-229231-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"9eb354c8d3b1adb788119979b27a9bfc727893b1","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-08-28T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-10-06","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":"$10.0 million","notice_date":"2025-08-22","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5450(b)(1)(A)","reported_value":"$7,069,000","rule_numbers":["5450(b)(1)(A)"],"rules_cited_in_text":true},"claim":"Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).","evidence_excerpt":"August 22, 2025, Xilio Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirement to maintain a minimum of $10.0 million in stockholders’ equity, as required by Nasdaq Listing Rule 5450(b)(1)(A) for continued listing on The Nasdaq Global Select Market. As stated in the Letter, the Company reported stockholders’ equity of $7,069,000 in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-011802","anchor_url":"https://secwatch.observer/filing/0001558370-25-011802#claim-9eb354c8d3b1adb788119979b27a9bfc727893b1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025011802/0001558370-25-011802-index.htm"},{"fact_type":"executive_change","fact_key":"95b59958b5","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-06-10T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-10","interim":false,"role":"Class II director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Akintunde Bello was elected as Class II director at Xilio Therapeutics, Inc..","evidence_excerpt":"elected Akintunde Bello, Ph.D., as a Class II director of the Company","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001558370-25-008512","anchor_url":"https://secwatch.observer/filing/0001558370-25-008512#claim-95b59958b5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025008512/0001558370-25-008512-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"22c33cd2b1c836f765db76a7abbc95d8b11d18c1","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-04-08T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":"2025-10-01","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"$1.00 per share for at least 10 consecutive business days","notice_date":"2025-04-04","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5450(a)(1)","reported_value":null,"rule_numbers":["5450(a)(1)"],"rules_cited_in_text":true},"claim":"Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"April 4, 2025, Xilio Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). ​ The Notice has no immediate effect on the listing of the Company’s common","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-25-004599","anchor_url":"https://secwatch.observer/filing/0001558370-25-004599#claim-22c33cd2b1c836f765db76a7abbc95d8b11d18c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025004599/0001558370-25-004599-index.htm"},{"fact_type":"executive_change","fact_key":"8fc490443f","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-06-13T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-13","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"James Shannon was elected as Class I Director at Xilio Therapeutics, Inc..","evidence_excerpt":"elected James Shannon, M.D., as a Class I director of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-009138","anchor_url":"https://secwatch.observer/filing/0001558370-24-009138#claim-8fc490443f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024009138/0001558370-24-009138-index.htm"},{"fact_type":"earnings_release","fact_key":"c3d4d2240406e7366ddeebff5cab50a71cf3fc0c","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"quarter ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"Xilio Therapeutics, Inc. reported financial results for quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024 and other business highlights.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-008063","anchor_url":"https://secwatch.observer/filing/0001558370-24-008063#claim-c3d4d2240406e7366ddeebff5cab50a71cf3fc0c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024008063/0001558370-24-008063-index.htm"},{"fact_type":"earnings_release","fact_key":"e93978c1196b6dc0227dc38bea42ab66f7528436","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-04-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fourth quarter and full year ended December 31, 2023","report_date":"2024-04-01","result_type":"reported_results","revenue_text":null},"claim":"Xilio Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2023.","confidence":0.93,"filing_url":"https://secwatch.observer/filing/0001558370-24-004528","anchor_url":"https://secwatch.observer/filing/0001558370-24-004528#claim-e93978c1196b6dc0227dc38bea42ab66f7528436","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024004528/0001558370-24-004528-index.htm"},{"fact_type":"restructuring_charge","fact_key":"c54c4e76150ddc5519ab12a75ff0efae6b3e6acd","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"approximately $1.0 million","effective_date":"2024-03-27","event_type":"restructuring","headcount_text":"a reduction in headcount of 15 employees, representing approximately 21% of the Company's current workforce","item_codes_triggered":["2.05"]},"claim":"Xilio Therapeutics, Inc. announced a restructuring with charges of approximately $1.0 million (a reduction in headcount of 15 employees, representing approximately 21% of the Company's current workforce).","evidence_excerpt":"the Company expects to incur one-time costs of approximately $1.0 million, primarily related to cash expenditures for severance and benefits continuation.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-004165","anchor_url":"https://secwatch.observer/filing/0001558370-24-004165#claim-c54c4e76150ddc5519ab12a75ff0efae6b3e6acd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024004165/0001558370-24-004165-index.htm"},{"fact_type":"material_agreement","fact_key":"be016270459c03e0e87c8fa1706f00a65e79e006","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Investor Rights Agreement","agreement_type":"equity_purchase","counterparty":"Gilead Sciences, Inc.","effective_date":"2024-03-27","item_codes_triggered":["1.01"],"value_text":null},"claim":"Xilio Therapeutics, Inc. entered into Investor Rights Agreement with Gilead Sciences, Inc. (effective 2024-03-27).","evidence_excerpt":"Pursuant to the terms of an investor rights agreement (the \"Investor Rights Agreement\") to be entered into between Gilead and the Company at the closing of the Initial Gilead Private Placement","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0001558370-24-004165","anchor_url":"https://secwatch.observer/filing/0001558370-24-004165#claim-be016270459c03e0e87c8fa1706f00a65e79e006","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024004165/0001558370-24-004165-index.htm"},{"fact_type":"material_agreement","fact_key":"2fc6e60d682a95eefbdf5f935bbb2b8b0de92b69","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Stock Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Gilead Sciences, Inc.","effective_date":"2024-03-27","item_codes_triggered":["1.01"],"value_text":"approximately $13.5 million"},"claim":"Xilio Therapeutics, Inc. entered into Stock Purchase Agreement with Gilead Sciences, Inc. valued at approximately $13.5 million (effective 2024-03-27).","evidence_excerpt":"on March 27, 2024, the Company entered into a stock purchase agreement with Gilead (the \"Stock Purchase Agreement\") pursuant to which the Company agreed to initially issue and sell 6,860,223 of its shares of Common Stock to Gilead in a private placement at a purchase price of $1.97 per share for an aggregate purchase price of approximately $13.5 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-004165","anchor_url":"https://secwatch.observer/filing/0001558370-24-004165#claim-2fc6e60d682a95eefbdf5f935bbb2b8b0de92b69","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024004165/0001558370-24-004165-index.htm"},{"fact_type":"material_agreement","fact_key":"23d8f5f75e5d7f752be42541644a1684d6e1140b","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License Agreement","agreement_type":"license","counterparty":"Gilead Sciences, Inc.","effective_date":"2024-03-27","item_codes_triggered":["1.01"],"value_text":"approximately $43.5 million in upfront payments"},"claim":"Xilio Therapeutics, Inc. entered into License Agreement with Gilead Sciences, Inc. valued at approximately $43.5 million in upfront payments (effective 2024-03-27).","evidence_excerpt":"On March 27, 2024, Xilio Development, Inc. (\"Xilio Development\"), a wholly-owned subsidiary of Xilio Therapeutics, Inc. (the \"Company\"), entered into an exclusive license agreement (the \"License Agreement\") with Gilead Sciences, Inc. (\"Gilead\")","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-24-004165","anchor_url":"https://secwatch.observer/filing/0001558370-24-004165#claim-23d8f5f75e5d7f752be42541644a1684d6e1140b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024004165/0001558370-24-004165-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"dfb0a6f1b9d90f54c090ae6c91685fb66a5dabfa","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2024-01-19T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"deficient","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2024-01-19","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5450(a)(1)"],"rules_cited_in_text":true},"claim":"Xilio Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"January 19, 2024, Xilio Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). ​ The Notice has no immediate effect on the listing of the Company’s com","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-24-000383","anchor_url":"https://secwatch.observer/filing/0001558370-24-000383#claim-dfb0a6f1b9d90f54c090ae6c91685fb66a5dabfa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837024000383/0001558370-24-000383-index.htm"},{"fact_type":"earnings_release","fact_key":"6cc725ce906f3e75a1ed77e6ad5c1ea9513f8514","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-09","result_type":"reported_results","revenue_text":null},"claim":"Xilio Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001558370-23-018578","anchor_url":"https://secwatch.observer/filing/0001558370-23-018578#claim-6cc725ce906f3e75a1ed77e6ad5c1ea9513f8514","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023018578/0001558370-23-018578-index.htm"},{"fact_type":"executive_change","fact_key":"4c538c9cf1","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-09-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-09-08","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"René Russo was appointed as President at Xilio Therapeutics, Inc..","evidence_excerpt":"Effective September 8, 2023, the board of directors (the “Board”) of the Company appointed René Russo, Pharm.D., 48, to President of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-23-015426","anchor_url":"https://secwatch.observer/filing/0001558370-23-015426#claim-4c538c9cf1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/0001558370-23-015426-index.htm"},{"fact_type":"executive_change","fact_key":"ceca490d08","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-09-05T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-09-08","interim":false,"role":"President and Head of Research and Development","role_category":"president","successor_name":"René Russo","successor_named":true},"claim":"Martin Huber resigned as President and Head of Research and Development at Xilio Therapeutics, Inc..","evidence_excerpt":"Martin Huber, M.D., notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as President and Head of Research and Development of the Company, effective September 8, 2023, to pursue other opportunities.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-23-015426","anchor_url":"https://secwatch.observer/filing/0001558370-23-015426#claim-ceca490d08","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023015426/0001558370-23-015426-index.htm"},{"fact_type":"earnings_release","fact_key":"a1b764b4373b645d88c1b5f7e430354577ff9a63","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the second quarter ended June 30, 2023","report_date":"2023-08-14","result_type":"reported_results","revenue_text":null},"claim":"Xilio Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023 and other business highlights.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001558370-23-014708","anchor_url":"https://secwatch.observer/filing/0001558370-23-014708#claim-a1b764b4373b645d88c1b5f7e430354577ff9a63","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023014708/0001558370-23-014708-index.htm"},{"fact_type":"executive_change","fact_key":"768c80d517","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2023-08-03","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Christopher Frankenfield changed role as Chief Operating Officer at Xilio Therapeutics, Inc..","evidence_excerpt":"On August 3, 2023, the board of directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) promoted Christopher Frankenfield, the Company’s Chief Legal and Administrative Officer, to the position of Chief Operating Officer, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-23-013235","anchor_url":"https://secwatch.observer/filing/0001558370-23-013235#claim-768c80d517","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023013235/0001558370-23-013235-index.htm"},{"fact_type":"shareholder_vote","fact_key":"51252ce150eaf277efc3681ebc05d59b23bf3d00","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-06-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-08","outcome":"passed","proposal_text":"Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"230,537","votes_against":"1,623","votes_for":"21,955,354","votes_withheld":null}]},"claim":"Xilio Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.","evidence_excerpt":"2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-23-011031","anchor_url":"https://secwatch.observer/filing/0001558370-23-011031#claim-51252ce150eaf277efc3681ebc05d59b23bf3d00","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/0001558370-23-011031-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5a2275be49c6b2d80397fcac1d5b7e38348a9e0e","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-06-13T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-08","outcome":"passed","proposal_text":"Election of Class II Directors","proposal_type":"director_election","results":[{"broker_non_votes":"3,812,216","subject":"Daniel Curran, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"17,836,373","votes_withheld":"538,925"},{"broker_non_votes":"3,812,216","subject":"Robert Ross, M.D.","votes_abstain":null,"votes_against":null,"votes_for":"18,136,312","votes_withheld":"238,986"},{"broker_non_votes":"3,812,216","subject":"Yuan Xu, Ph.D.","votes_abstain":null,"votes_against":null,"votes_for":"17,836,313","votes_withheld":"538,985"}]},"claim":"Xilio Therapeutics, Inc. shareholders approved Election of Class II Directors at the 2023-06-08 meeting.","evidence_excerpt":"1. The Company’s stockholders elected Daniel Curran, M.D., Robert Ross, M.D., and Yuan Xu, Ph.D., as Class II directors, each to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-23-011031","anchor_url":"https://secwatch.observer/filing/0001558370-23-011031#claim-5a2275be49c6b2d80397fcac1d5b7e38348a9e0e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023011031/0001558370-23-011031-index.htm"},{"fact_type":"earnings_release","fact_key":"609f747d767711d2745776d2ea409e2cd53781d2","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$22.6 million","period_text":"first quarter ended March 31, 2023","report_date":"2023-05-09","result_type":"reported_results","revenue_text":null},"claim":"Xilio Therapeutics, Inc. reported first quarter ended March 31, 2023 results: net income $22.6 million.","evidence_excerpt":"Xilio Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter ended March 31, 2023 and other business highlights.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001558370-23-008673","anchor_url":"https://secwatch.observer/filing/0001558370-23-008673#claim-609f747d767711d2745776d2ea409e2cd53781d2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023008673/0001558370-23-008673-index.htm"},{"fact_type":"governance_change","fact_key":"3b9ff6220ce37a754f771ba960874cdb68a29443","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-04-03T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-03-28","item_codes_triggered":["5.03"],"summary_text":"Adopted Second Amended and Restated Bylaws to amend stockholder meeting procedures, voting list requirements, adjournment procedures, advance notice requirements, proxy card color, eliminate director compensation provision, and make technical and conforming changes."},"claim":"Xilio Therapeutics, Inc.: Adopted Second Amended and Restated Bylaws to amend stockholder meeting procedures, voting list requirements, adjournment procedures, advance notice requirements, proxy card color, eliminate director compensation provision, and make technical and conforming changes (effective 2023-03-28).","evidence_excerpt":"On March 28, 2023, the Board adopted amended and restated bylaws of the Company (as amended and restated, the “Second Amended and Restated Bylaws”), effective immediately","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-23-005393","anchor_url":"https://secwatch.observer/filing/0001558370-23-005393#claim-3b9ff6220ce37a754f771ba960874cdb68a29443","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/0001558370-23-005393-index.htm"},{"fact_type":"executive_change","fact_key":"b3ae66b470","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-04-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-30","interim":false,"role":"Senior Vice President, Finance and Accounting","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Kevin Brennan was appointed as Senior Vice President, Finance and Accounting at Xilio Therapeutics, Inc..","evidence_excerpt":"On March 30, 2023, Kevin Brennan joined Xilio Therapeutics, Inc. (the “Company”) as Senior Vice President, Finance and Accounting, and the board of directors (the “Board”) of the Company appointed Mr. Brennan to serve as the Company’s principal financial officer and principal accounting officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-23-005393","anchor_url":"https://secwatch.observer/filing/0001558370-23-005393#claim-b3ae66b470","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023005393/0001558370-23-005393-index.htm"},{"fact_type":"earnings_release","fact_key":"632026996df838f78ae61596a283a49ad677f0b9","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2023-03-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and full year ended December 31, 2022","report_date":"2023-03-02","result_type":"reported_results","revenue_text":null},"claim":"Xilio Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 2, 2023, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 and other business highlights.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001558370-23-002685","anchor_url":"https://secwatch.observer/filing/0001558370-23-002685#claim-632026996df838f78ae61596a283a49ad677f0b9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837023002685/0001558370-23-002685-index.htm"},{"fact_type":"executive_change","fact_key":"b55dd764f7","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-12-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-01-31","interim":false,"role":"vice president, finance, accounting and treasury and principal accounting officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Edward C. English resigned as vice president, finance, accounting and treasury and principal accounting officer at Xilio Therapeutics, Inc..","evidence_excerpt":"On December 19, 2022, Edward C. English notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as vice president, finance, accounting and treasury and principal accounting officer of the Company, effective January 31, 2023, to pursue other opportunities.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001544784-22-000009","anchor_url":"https://secwatch.observer/filing/0001544784-22-000009#claim-b55dd764f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000154478422000009/0001544784-22-000009-index.htm"},{"fact_type":"earnings_release","fact_key":"095a68e1bada6f2390771b271e53468e71201fcd","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter ended September 30, 2022","report_date":"2022-11-09","result_type":"reported_results","revenue_text":null},"claim":"Xilio Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001558370-22-017015","anchor_url":"https://secwatch.observer/filing/0001558370-22-017015#claim-095a68e1bada6f2390771b271e53468e71201fcd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022017015/0001558370-22-017015-index.htm"},{"fact_type":"executive_change","fact_key":"ca114c6888","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-09-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-09-15","interim":false,"role":"Class I director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Tomas Heyman was appointed as Class I director at Xilio Therapeutics, Inc..","evidence_excerpt":"Effective September 15, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Tomas Heyman to the Board as a Class I director of the Company, to serve in such capacity until the Company’s 2025 annual meeting of stockholders or until his earlier resignation, death, or removal.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-22-014430","anchor_url":"https://secwatch.observer/filing/0001558370-22-014430#claim-ca114c6888","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022014430/0001558370-22-014430-index.htm"},{"fact_type":"executive_change","fact_key":"c951b1d5ed","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-07-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-08-19","interim":false,"role":"chief financial officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Salvatore Giovine resigned as chief financial officer at Xilio Therapeutics, Inc..","evidence_excerpt":"On July 25, 2022, Salvatore Giovine notified Xilio Therapeutics, Inc. (the “Company”) of his decision to resign as chief financial officer (principal financial officer) of the Company, effective August 19, 2022, for personal family reasons.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-22-011295","anchor_url":"https://secwatch.observer/filing/0001558370-22-011295#claim-c951b1d5ed","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022011295/0001558370-22-011295-index.htm"},{"fact_type":"executive_change","fact_key":"2079fb998a","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-06-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-06-15","interim":false,"role":"Class II director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Robert Ross was appointed as Class II director at Xilio Therapeutics, Inc..","evidence_excerpt":"Effective June 15, 2022, the Board, on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Ross, M.D. to the Board as a Class II director of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-22-010062","anchor_url":"https://secwatch.observer/filing/0001558370-22-010062#claim-2079fb998a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/0001558370-22-010062-index.htm"},{"fact_type":"executive_change","fact_key":"e5382272d6","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-06-16T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-06-15","interim":false,"role":"President","role_category":"president","successor_name":null,"successor_named":false},"claim":"Martin Huber changed role as President at Xilio Therapeutics, Inc..","evidence_excerpt":"On June 15, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) promoted Martin Huber, M.D., 62, to President of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-22-010062","anchor_url":"https://secwatch.observer/filing/0001558370-22-010062#claim-e5382272d6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022010062/0001558370-22-010062-index.htm"},{"fact_type":"executive_change","fact_key":"e6edb82744","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-02-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-02-03","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Rachel Humphrey resigned as director at Xilio Therapeutics, Inc..","evidence_excerpt":"On February 3, 2022, Rachel Humphrey, M.D. notified Xilio Therapeutics, Inc. (the “Company”) of her decision to resign from the board of directors of the Company effective as of such date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-22-000789","anchor_url":"https://secwatch.observer/filing/0001558370-22-000789#claim-e6edb82744","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022000789/0001558370-22-000789-index.htm"},{"fact_type":"executive_change","fact_key":"37fd0d76cf","cik":1840233,"ticker":"XLO","company_name":"Xilio Therapeutics, Inc.","filed_at":"2022-01-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-01-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Yuan Xu was appointed as Director at Xilio Therapeutics, Inc..","evidence_excerpt":"Effective January 4, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Yuan Xu, Ph.D. to fill a newly created vacancy on the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001558370-22-000083","anchor_url":"https://secwatch.observer/filing/0001558370-22-000083#claim-37fd0d76cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1840233/000155837022000083/0001558370-22-000083-index.htm"}]}